The Wilms tumor-suppressor gene WT1, a key player in renal development, also has a crucial role in maintenance of the glomerulus in the mature kidney. However, molecular pathways orchestrated by WT1 in podocytes, where it is highly expressed, remain unknown. Their defects are thought to modify the cross-talk between podocytes and other glomerular cells and ultimately lead to glomerular sclerosis, as observed in diffuse mesangial sclerosis (DMS) a nephropathy associated with WT1 mutations.
INTRODUCTION
Glomeruli are specialized structures responsible for blood filtration in the kidney and are the targets of injury in a number of human diseases. They are formed of four cell types; endothelial cells, supporting mesangial cells that sit between the capillary loops in their mesangial matrix, visceral epithelial cells (podocytes) and parietal epithelial cells of Bowman's capsule. Podocytes are "octopus-like" cells, comprising a cell body and cytoplasmic extensions that divide into actin-rich foot processes that interdigitate to envelop the capillary loops. Neighboring foot processes are attached laterally along their length by a highly specialized intercellular junction termed the slit diaphragm (1), and they also adhere along their basal aspect to the glomerular basement membrane (GBM). Plasma is ultrafiltered through the fenestrated endothelium, then the GBM, and finally through the slit diaphragm.
Coordinated cross-talk between glomerular cells is required for the formation and maintenance of a functional filtration barrier. This is illustrated by the development of diffuse mesangial sclerosis (DMS), a nephropathy associated with mutations in genes encoding podocyte proteins (2) and characterized by rapid progression of glomerular lesions from a discrete increase in mesangial matrix to massive mesangial sclerosis. The disease progresses to end-stage renal failure usually before the age of 5 years. DMS is a hallmark feature of Denys-Drash syndrome (DDS), a rare disorder affecting urogenital development characterized by the association of early onset nephrotic syndrome, male pseudohermaphroditism, and predisposition to Wilms tumor (3, 4) . Constitutional heterozygous mutations of WT1 have been demonstrated in nearly all DDS patients, and also in some cases of sporadic nonsyndromic DMS in the absence of genital defects and Wilms tumor (5) . Isolated DMS can also be associated with PLCE1 and LAMB2 mutations (6, 7) , but in some cases are not linked to any known gene or locus (C. Antignac, unpublished data).
The WT1 gene encodes multiple isoforms of a zinc finger containing protein that regulates gene expression at both the transcriptional and post-transcriptional levels (8, 9) . It functions as a tumor suppressor and is involved in about 10% of Wilms tumors, a childhood kidney cancer derived from embryonic mesenchymal cells. WT1 plays a crucial role in kidney and gonad development (10) . In the mature kidney, it is expressed exclusively in the glomerular epithelial cells. WT1 mutations associated with DDS are thought to act in a dominant negative manner. Evidence for this comes firstly from the fact that patients with large deletion involving WT1 among other genes display WAGR syndrome (Wilms tumor, aniridia, genital abnormalities and mental retardation) but do not develop early glomerular disease. Secondly, DDS mutations are consistently located in exons 8 and 9 of the gene (with a hot spot p.Arg394Trp missense mutation) and interrupt the normal DNA binding of the protein but not its ability to dimerize in vitro (11) .
Several WT1 target genes have been identified in vitro (12, 13 ) but very few have been validated in vivo. In the kidney, WT1 targets and molecular pathways involved in the development of DMS are still largely unknown, although Wt1 mutant mice have provided some clues (reviewed in (14) ). Nphs1, encoding the slit diaphragm protein nephrin, and Podxl, encoding an anti-adhesive glycoprotein expressed abundantly by podocytes, are downregulated in mice with reduced expression of Wt1 that develop glomerulosclerosis but also show severe defects in kidney development and possibly in nephron number (15) . Downregulation of these genes is not a feature of another mouse model that more genuinely reproduces the glomerular lesions observed in human DDS (16) .
We generated a novel mouse line carrying the p.Arg394Trp DDS mutation that develops strain-dependent glomerulosclerosis, as previously reported (16) . Through transcriptional profiling of mutant glomeruli taken before the development of severe mesangial lesions, we identified three genes that are likely involved in DMS. Two of them are direct transcriptional targets of WT1: Scel, encoding sciellin, a precursor of the cornified envelope in the skin, which is shown here for the first time to be expressed in human and mouse podocytes, and Sulf1, encoding a 6-O-endosulfatase. The down-regulation of Sulf1 was associated with a decreased labeling of low sulfated heparan sulfate chains in the GBM, and can be anticipated to modify growth factors activity in the glomerulus. The third one, Cyp26a1, encoding a cytochrome P450 enzyme involved in degradation of all-trans retinoic acid, may not be regulated by WT1.
RESULTS
Mice heterozygous for the Wt1 p.Arg394Trp mutation develop strain-dependant diffuse mesangial sclerosis. Figure   1) were injected into C57BL/6 blastocysts, produced chimeras and heterozygous Wt1 +/mut mice. The phenotype described hereafter was the same in mice derived from either clone. As previously reported by others (16) , heterozygous mice on a mixed C57BL/6J X 129Sv/Pas (B6X129) background (n=9) were healthy and fertile, displayed no proteinuria or renal failure after several months (mean 5.5 months, range 3.5-10 months), and had normal renal histology.
Two 129Sv ES cell clones bearing the p.Arg394Trp mutation (Supplementary
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+/mut mice were crossed onto B6 and FVB/NCrl (FVB) backgrounds.
Mutants did not display any proteinuria after 4 generations of crossing onto B6 background.
Conversely, 6 of 9 males of the N1-FVB (first generation of cross onto the FVB background) developed heavy proteinuria between 2 and 8 months, and all males of the N2, N3 or N4 generations (n=26) developed proteinuria by 2 weeks (the earliest point when urine sample was checked) and 2 months. The average lifespan of FVB mutant males (one N2, 7 N3 and 6 N4) was 4.6 months (range 1.5-9.7 months) and necropsy showed massive glomerular sclerosis with tubular damages. Females also developed renal disease, although females were affected later. In contrast to humans, genital development appeared completely normal in male and female mutants. In FVB mutant males, GBM thickening was observed by the onset of proteinuria but before the development of mesangial alterations, and this was sometimes associated with podocytes hypertrophy and vacuolation ( Figure 1A ). It was linked to GBM irregularities with subepithelial expansions visible on silver stain ( Figure 1D ).
Immunofluorescence analysis showed mesangial and parietal staining with anti-IgG ( Figure   1B , 1C) and anti-IgM antibodies, but no electron-dense deposits were visible at the ultrastructural level ( Figure 1F ). As previously reported in human DDS (17, 18) , complex alterations of the GBM with spiky projections were present ( Figure 1F ), focally associated with foot process effacement. Subsequently, both mesangiolysis ( Figure 1G ) and mesangial sclerosis ( Figure 1H ) were present associated with dramatic podocyte abnormalities, tubular dilatation and tubular cylinders ( Figure 1I ). Glomerular lesions were frequently more severe at the periphery of the cortex, whereas deeper glomeruli, although enlarged, were less severely affected.
Expression levels of mutant and wild-type Wt1 alleles are strain-dependent.
By real time PCR, the total level of Wt1 RNAs was about twice in the mixed B6X129
background, compared to the FVB background ( Figure 2A ). In either background the total level of Wt1 RNAs was the same in Wt1 +/mut and in Wt1 +/+ glomeruli ( Figure 2A Figure 3A ) and Sulf1 (28 fold) ( Figure 3B ), and the up-regulation of Cyp26a1 (16 fold) ( Figure 3C ). On the mixed genetic background there was a comparable downregulation of Scel (26 fold, Figure 3A ) and up-regulation of Cyp26a1 (22 fold, Figure 3C ).
Interestingly, down-regulation of Sulf1 on the mixed background was modest compared to the FVB background (2.2 vs. 28 fold, Figure 3B ). As only FVB mice develop glomerular disease, these results suggest that the reduction of Sulf1 expression may play an important role in the pathogenesis of the glomerular lesions.
Localization of Cyp26a1, Sulf1 and Scel RNAs and/or proteins in wild-type and mutant
kidneys.
In situ hybridization using Cyp26a1, Sulf1 and Scel murine cDNA probes was Glomeruli from both wild-type and mutant mice were negative using an antisense probe to
Scel (results not shown). Immunostaining was performed using a sciellin antibody (19) as sciellin mRNAs might normally be expressed below the limit of detection by in situ hybridization. The specificity of this antibody has previously been established based on its labeling of wild type but not Scel -/-skin (20) . Sciellin was detected in a quasi-linear pattern along glomerular capillary walls in wild-type mice ( Figure 5A ), and the signal co-localized with nephrin demonstrating its expression by podocytes ( Figures 5B, 5C , 5G). Dual labeling for sciellin and the basement membrane marker nidogen ( Figure 5H ) revealed sciellin positive cells along the external aspect of the GBM, supporting their identification as podocytes.
Labeling for nephrin was conserved in Wt1 +/mut glomeruli, whereas sciellin was obviously reduced compared to controls ( Figures 5D, 5E , 5F) and this difference was more pronounced in deep glomeruli than in superficial glomeruli. The same sciellin antibody also labeled glomeruli of normal mature human kidney in a pattern consistent with podocyte expression ( Figure 5I ). Figure 7A ). As expected, Sulf1 and Scel were expressed in M15 but not in HEK293 and, conversely, Cyp26a1 was expressed to a higher extent in HEK293 than in M15 cells ( Figure 7A ). To provide a further argument for the regulation of these genes by WT1, their expression was evaluated following siRNA-mediated knock-down of WT1 in M15 cells. Wt1 mRNA levels were reduced by 80% and 53% in siRNA transfected cells at 24 (not shown) and 48 hours ( Figure   7C ) post-transfection, respectively. Western blot revealed at 24 hours a corresponding marked decrease in WT1 protein, which became almost undetectable by 48 hours ( Figure 7B ). At this time, the levels of Sulf1 and Scel mRNA in Wt1 knockdown cells were decreased by 40%
and 70% ( Figure 7C ), and western blotting confirmed down-regulation of both genes at the protein level ( Figures 7D, 7E ). These findings suggest that both Scel and Sulf1 are regulated by WT1. In contrast, Cyp26a1 mRNA levels were not significantly changed 24 and 48 hours following WT1 knock-down ( Figure 7C ).
WT1 binds cis-acting control elements of the Scel and Sulf1 genes
Because Scel and Sulf1 seemed to be regulated by WT1, we used chromatin immunoprecipitation (ChIP) assay to determine whether these putative targets were directly or indirectly regulated by WT1. Known WT1 target sequences from the literature were used to generate a matrix representing a WT1-bound consensus sequence ( Figure 8A ). Using an in silico analysis, we looked for predicted WT1 binding sites in the 200 kb sequences flanking the transcription initiation start sites of Sulf1 and Scel. We selected sites that were conserved in at least 4 species including human and mouse and/or that were the closest to the consensus sequence, as represented by the score ( Figure 8B ). To test whether these top scoring candidates were actually bound by WT1 in M15 cells, nuclear extracts were immunoprecipitated using either a rabbit anti-WT1 polyclonal antibody or control IgG, and binding was assessed by quantitative PCR. Calculations for the DNA enrichment are detailed in methods. When significant enrichment was found, we repeated the ChIP assay after WT1
knock-down in order to show that the binding did correlate with WT1 expression. The Amhr2
promoter was used as a positive control for WT1-bound sequence (24) (the putative binding site in that sequence has a score of 2.9 with our in silico analysis). As expected there was a 8.1 fold DNA enrichment for this sequence in WT1-precipitated complexes, and this enrichment was decreased to 1.2 fold after WT1 knock-down ( Figure 8C ). Likewise, there was no significant enrichment with a negative control region located around 10 kb distal to the Cyp26a1 gene that lacked potential WT1 binding sites. For Scel we identified 3 elements that were significantly enriched after ChIP with anti-WT1 antibodies. However, only one of them showed a significant decrease of the binding after WT1 knock-down. This element is localized 42 kb upstream of the gene, shows a 2.5 fold enrichment, which decreased to 1.7
after Wt1 siRNA transfection ( Figure 8C ). For Sulf1, we identified 2 elements with a significant enrichment which decreased only for one of them after WT1 knock-down. This sequence is localized 26 kb upstream of the transcriptional starting site and shows a 8.5 fold enrichment that decreased to 4.3 after Wt1 siRNA transfection ( Figure 8C ). In summary, our data demonstrate that WT1 interacts with cis sequences of Scel and Sulf1 genes, and thus that these genes are direct WT1 targets.
DISCUSSION
To identify novel WT1 target genes in the podocyte involved in the development of DMS we generated mice carrying a heterozygous DDS Wt1 mutation and used glomerular RNAs isolated from mutant and wild-type mice to perform whole genome expression profiling. As previously reported (16), we observed no phenotype associated with the p.Arg394Trp Wt1 heterozygous mutation on a mixed B6X129 background. However, we
showed that the mutation is associated with a severe renal phenotype on an inbred FVB background that mirrors that in human DDS. Mutant mice develop heavy proteinuria associated with podocyte hypertrophy, mesangial sclerosis and mesangiolysis. It is interesting to note that mice carrying a null Wt1 allele have been reported previously to develop renal abnormalities earlier on a FVB background than on a mixed background (25) .
Although the mice used for expression screening were not truly congenic, after four generations of backcrossing mutants would be expected to harbor 93.75% of the recipient genome thereby substantially reducing variability due to genetic heterogeneity. On both backgrounds, we found the same level of total Wt1 RNA in mutant and wild-type mice, and the wild-type transcript in Wt1 +/mut represents about 50% of the Wt1 transcripts in Wt1 +/+ .
Thus, the ratio between mutant and wild-type RNA is the same in both backgrounds, but the level of expression of either transcript is halved in mice on the sensitive FVB background compared to the resistant B6X129 background. These results are in agreement with data published by Gao and colleagues (16) . Whether or not the mutant protein has some level of dominant negative activity on the wild-type protein, our results are in agreement with a model in which a threshold level of WT1 expression is required for podocyte homeostasis in the mature kidney. These data suggest that the transcriptional level of Wt1 may explain, at least in part, the differences in renal phenotype severity according to the mouse strain. The role of factors acting in trans in the regulation of Wt1 RNA is illustrated by the 50% reduction of the mutant transcript on the FVB background (as the mutant allele always remains a 129 Wt1 allele, even after several backcrosses).
Among the 36 genes that were most significantly up-or down-regulated in Wt1
glomeruli, none encode growth factors or podocyte proteins known to be involved in glomerular diseases in humans or mice. Three seemed to us to be excellent candidate genes influencing the development of glomerular lesions. The expression of sciellin, a precursor of the cornified cell envelope, was more than 30 fold down-regulated in Wt1 +/mut glomeruli. The cornified envelope is a highly cross-linked and resilient structure just inside the plasma membrane of some differentiated cells in stratified squamous epithelia (skin, oral cavity, esophagus, vagina) (26, 27) . Sciellin is believed to participate in the ability of these tissues to withstand chemical and biomechanical stress and to provide a protective barrier against the environment. It is also expressed in amnion (28) and in the intima of large diameter arteries, and was recently shown to be up-regulated during arterialization of veins (29) , suggesting that it is involved in stress-bearing properties. We show here for the first time that sciellin is expressed in glomerular podocytes in mice and humans, that the gene is a direct WT1 target, and that sciellin protein is down-regulated in Wt1 +/mut glomeruli. Although we have not yet determined the subcellular localization of sciellin in podocytes, its colocalization with nephrin suggests that it might be in part localized to the area of the slit diaphragm in podocyte foot processes. Beyond its role of a signaling platform (30) , the slit diaphragm presumably participates in counteracting the pressure mediated capillary expansion, reinforces the structure against tensile forces resulting from filtration pressures (31, 32) , and contributes to the size limit of the glomerular filter (33) . Several authors have shown that podocytes respond to mechanical stress (32, 34, 35) , and the slit diaphragm has been recently considered as a mechanosensor (36, 37). Glomerular capillary hypertension, or alternatively altered podocyte mechanosensation, may cause abnormal podocyte contractile function, podocyte hypertrophy, and/or podocytopenia (38), and ultimately lead to glomerulosclerosis. Given its role in epithelia and arteries, it is tempting to speculate that sciellin may play a role in the stress bearing properties of podocytes. However, sciellin down-regulation may not be a sufficient event for DMS development. Indeed, the strong sciellin down-regulation also occurs in should be tried as therapeutic agents in DMS, and they can be tested in our mouse model.
In conclusion, we characterized a mouse model reproducing the human DDS nephropathy and, by using a global gene expression profiling, we identified deregulated genes potentially involved in the development of DMS either through podocyte dedifferentiation or through modification of growth factor signaling in the glomerulus. Two of these genes, Scel and Sulf1, encode proteins that were not known to be expressed in podocytes and are direct WT1 targets. These results provide novel insights in our knowledge of the structure and function of the mature glomerulus and into early mechanisms leading to glomerular sclerosis.
In addition, these data open new avenues for novel therapeutic approaches in DMS. 
MATERIAL AND METHODS
Generation of
Phenotypic characterization.
Urine was collected during handling of mice and 1µl samples analyzed by electrophoresis on 12% SDS-PAGE gels, followed by Coomassie blue staining. Albumin was quantified against a standard curve. Histological and electron microscopy analysis were performed as described (58) .
Glomeruli RNA preparation and microarray experiment.
Isolation of glomeruli from mutant (FVB-N4 or 129xB6 background) and wild-type (FVB or 129xB6) was performed after cardiac Dynabead perfusion as described (59 The false discovery rate (FDR) of the test set was calculated using the Benjamini Hochberg procedure (60) . A FDR value of 5% was used to identify and restrict the number of differentially expressed genes.
Real-time PCR.
Glomerular RNA was extracted from 26-day-old mice using Qiagen's RNeasy Total RNA Isolation kit. Reverse transcription was performed using random primers and Superscript II reverse transcriptase (Invitrogen, Eugene, OR). Gene expression was quantified in three mice per group and all experiments were carried in triplicate using the Stratagene Mx 3000P
apparatus. For the Wt1 allele-specific expression, we performed real-time SybrGreen assays using Wt1 allele specific primers that were as follows: for the wild-type allele, sense Hs01103754-m1; Scel: Mm00452200-m1; SCEL: Hs00187213-m1; Sulf1: Mm00552283-m1;
SULF1: Hs00290918-m1; Cyp26a1: Mm00514486-m1; CYP26A1: Hs00175627; Hprt1:
Mm01545399-m1; 18S: Hs99999901-s1. Target gene expression, normalized to Hprt1 RNA in mice or to 18S RNA in cells, were calculated using the 2 -∆∆CT method.
Riboprobes and in situ hybridization.
Sulf1, Cyp26a1 and Scel cDNA fragments were amplified by RT-PCR using Wt1 +/+ or Wt1 +/mut mature glomeruli total RNA and subcloned into pGEMT-easy vector (Promega, 
Restriction enzymes for linearization and RNA polymerases used for in vitro transcription
were NdeI/T7 RNA polymerase for the antisense probe and SacII/SP6 RNA polymerase for the sense probe. Labeled RNA probes were synthesized with digoxigenin-11-UTP (Roche, Meylan, France), according to the manufacturer's instructions. In situ hybridization was carried out as described elsewhere (61).
Immunofluorescence and immunohistochemistry.
Immunofluorescence staining was performed as described previously (58) . Kidney cryosections (10 µm) were fixed in acetone and incubated overnight at 4°C with the following antibodies; rabbit anti-sulfatase1 (1:100; Abcam, Cambridge, UK), guinea pig anti-nephrin (1:50; Progen, Heidelberg, Germany), rabbit anti-agrin LG (1:30000; kindly provided by T.
Sasaki, University of Erlangen-Nuernberg, Erlangen, Germany), rabbit anti-sciellin SC4 Immunoperoxidase staining for sciellin was performed on formaldehyde-fixed, paraffinembedded tissues as described elsewhere (62) . Primary antibody was incubated overnight at +4°C (dilution 1:600).
Cell culture and siRNA knock-down.
Human embryonic kidney cells (HEK293) and mouse mesonephros-derived M15 cells (23) were grown in Dulbecco's Modified Eagle's Medium (Sigma, St. Louis, MO) containing 10% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin and 0.1 mg/mL streptomycin.
Cells were grown at 37°C in humidified air with 7% CO 2 . Wt1 expression was silenced in 
Western blot
Cells were homogenized in 1% Triton, and protein samples (20 µg) were fractionated on 10%
SDS-PAGE gels and transferred onto Immobilon-P membranes (Millipore, Bedford, MA).
The membrane was blocked overnight in Tris-buffered saline, containing 0.1% Tween and 5% non-fat dry milk, and subsequently incubated for 2 hours with the following antibodies; mouse anti-WT1 mAb 6F-H2 (1:500, DakoCytomation, Glostrup, Denmark), rabbit antisciellin (1:2000) or rabbit anti-sulfatase1 (1:500). The membrane was washed and incubated with horseradish peroxidase-conjugated donkey anti-mouse or anti-rabbit antibodies
(1:10000; GE Healthcare, Buckinghamshire, UK) for one hour. A peroxidase-conjugated anti-GAPDH antibody was used as a loading control (1:30000, Sigma). The reaction products were visualized by ECL chemiluminescence using Hyperfilm MP (GE Healthcare).
Chromatin Immunoprecipitation (ChIP)
The identification of the conserved predicted WT1 binding sites was carried out as described previously (63) . Primers were designed using PrimerExpress 3.0 software and are listed in Supplementary   Table 2 . Quantification of precipitated DNA fragments was carried out on a Stratagene Mx 3000P sequence detection system using SYBR green in duplicate. Relative fold in vivo enrichment of DNA fragments was calculated as described elsewhere (64) 
